Dr Schimpff is the retired Chief Executive Officer of the University Medical Center.
Dr. Schimpff, an Eagle Scout, is a 1963 graduate of Rutgers University where he was a Henry Rutgers Scholar. He was also recipient of the Van Der Poole Award for Excellence in Medicinal Chemistry. He obtained his M.D. degree in 1967 at Yale Medical School and was inducted into Alpha Omega Alpha, the national medical honor society. His internal medicine internship and residency was at Yale-New Haven Hospital (1967-1969).
He was a Clinical Associate in the Baltimore Cancer Research Center (BCRC) of the National Cancer Institute from 1969-1972. He was a Fellow in the National Institute of Allergy and Infectious Diseases, NIH, from 1972-1973. He is Board certified in Internal Medicine, Medical Oncology and Infectious Diseases.
Dr. Schimpff was Senior Investigator in the National Cancer Institute’s BCRC from 1973 to1976. In 1976 he became Head, Section of Infectious Diseases and Microbiology at the BCRC and from 1979 was, concurrently, Head, Division of Infectious Diseases, Department of Medicine, at the University of Maryland School of Medicine.
He became internationally recognized for his research into the causes, prevention and treatment of infection in cancer patients undergoing aggressive cancer therapy. He has published over 200 scientific articles, reviews and book chapters and has edited three text books, including “Comprehensive Textbook of Oncology.” Clinically he devoted most of his time to treating patients with acute leukemia and lymphomas.
He was promoted to professor of medicine in the School of Medicine in 1979 and granted tenure in 1982. He was also appointed as professor of pharmacology and professor of oncology in 1982.
In 1982, he was appointed founding Director of the University of Maryland Cancer Center. In 1985, he became Executive Vice President and Chief Operating Officer of the newly created University of Maryland Medical System in Baltimore.
Dr. Schimpff became Chief Executive Officer of the Medical System’ s flagship, the University of Maryland Medical Center, in 1999. The Medical Center admits about 30,000 patients per year, largely for tertiary care, and includes the world’s preeminent trauma center and the country’s largest kidney transplant program. There are about 5000 staff with a budget of $750million; all medical care is provided by faculty of the School of Medicine.
In 2007, Dr. Schimpff authored The Future of Medicine, a book focusing on genomics, technology, imaging, stem cells, and the future of the OR and information management. Learn more about The Future of Medicine book and podcast at http://www.medicalmegatrends.com.
Dr. Schimpff is a consultant to the United States Army on mechanisms to interdigitate high technology into improved patient safety in the “operating room of the future.” He has been consultant to the Battelle Memorial Institute in techniques to assist states or institutions to increase translational research. Dr Schimpff is a board member of two developing medical technology companies.
He continues as a voluntary Professor of Medicine at the University of Maryland School of Medicine where he teaches residents and fellows in oncology and infectious diseases and recently became the lead on a proposal to the Department of Homeland Security to build and operate a biocontainment National Bio and Agro defense Facility.
Dr. Schimpff belongs to many societies and professional organizations including the EORTC’s International Anti-microbial Therapy Project Group of which he is a co-founder and the Multinational Association of Supportive Care in Cancer of which he is also a cofounder. He is a fellow of the American College of Physicians, a member of the American Society of Clinical Oncology, Infectious Diseases Society of America, the American Association of Cancer Research and has been active in the University Health System Consortium and the Association of American Medical Colleges. He was Treasurer of the American Society of Clinical Oncology from 1985 – 1989 and was a member of the National Board of Medical Examiners for six years.
Dr. Schimpff was chair of the Board of Governors of the National Institutes of Health’s Warren G. Magnuson Clinical Center from January 1999 until 2003; he was a board member since its inception in 1996 and member of the Board’s Executive Committee and chair of the Finance Working Group.
Civic activities have included the Downtown Partnership of Baltimore, Inc. Board of Directors and the March of Dimes, Maryland Chapter, Board of Directors. He was a member for ten years of the University of Maryland School of Pharmacy Board of Visitors. Dr. Schimpff served as a member of the boards of the Maryland Hospital Education Institute; the American Cancer Society, Maryland Division (President from 1990-1992); Maryland Association of Nonprofit Organizations (Chairman, Board of Directors from 1994-1997); the Maryland Hospital Association Board of Directors (1998- 2003); the Easter Seals Society of Maryland (Vice Chairman 1991-1992) and with his wife was co-leader of a Girl Scout Troop.
Dr Schimpff has been married to Carol Rawstrom Schimpff for 43 years. Mrs. Schimpff is a retired architect and commercial real estate pension advisor; she now docents at the Walters Art Museum. Their daughter, Elizabeth, is a CFA and former vice president of credit analysis at Merrill Lynch’s Tokyo office; she and her family have recently moved from Tokyo to Los Angeles.
1) Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentami¬cin for febrile patients with cancer and granulocytopenia, New England Journal of Medicine, 1971, 284, 1061-1065.
2) Schimpff SC, Wiernik PH, Block JB. Rectal abscesses in cancer patients, Lancet, 1972, ii, 844-847.
3) Schimpff SC, Greene WH, Young VM, Wiernik PH. Pseudomonas aeruginosa: its significance in the patient with leukemia or lymphoma, Journal of Infectious Diseases, 1974, 130, 524-531.
4) Schimpff SC, Schimpff CR, Brager DM, Wiernik PH. Leukemia and lymphoma patients interlinked by prior social contact, Lancet, 1975, i, 124.
5) Schimpff SC, Greene WH, Young VM, Fortner CL, Jepsen L, Cusack N, Block JB, Wiernik PH. Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation and, oral, nonab¬sorbable antibiotic prophylaxis, Annals of Internal Medicine, 1975, 82, 351-358.
6) Schimpff SC, Bennett JE. Abnormalities in cell-mediated immunity in patients with Crypto¬coc¬cus neoformans infec¬tion, Journal of Allergy and Clinical Immunology, 1975, 55, 430-441.
7) Schimpff SC. Diagnosis of infection in patients with cancer, European Journal of Cancer, 1975, 11, 29-38.
8) Aisner J, Schimpff SC, Sutherland JC, Young VM, Wiernik PH. Toru¬lopsis glabrata infections in patients with cancer: increasing inci¬dence and relationship to colonization, American Journal of Medicine, 1976, 61, 23-28.
9) Ruckdeschel JC, Schimpff SC, Smyth AC, Mardiney MR Jr. Herpes zoster and impaired cell-associated immunity to the varicella-zoster virus in patients with Hodgkin's disease, American Journal of Medi¬cine, 1977, 62, 77-85.
10) Aisner J, Schimpff SC, Wiernik PH, Treatment of invasive asper¬gil¬losis: relation of early diagnosis and treatment to response, Annals of Internal Medicine, 1977, 86, 539-543.
11) Murillo J, Standiford HC, Schimpff SC, Tatem BA. Comparison of serum bactericidal activity among three antimicrobial combinations. Antimicrobial Agents and Chemotherapy, 1978, 13, 992-996.
12) Murillo J, Schimpff SC, Brouillet MD. Axillary lesions in pa¬tients with acute leukemia: evaluation of a preventive program, Cancer, 1979, 43, 1493-1496.
13) Bender JF, Schimpff SC, Young VM, Fortner CL, Brouillet MD, Love LJ, Wiernik PH. The role of vancomycin as a component of oral nonab¬sorbable antibiotics for microbial suppres¬sion in leukemic patients, Antimicrobial Agents and Chemother¬apy, 1979, 15, 455-460.
14) Bender JF, Schimpff SC, Young VM, Fortner CL, Love LJ, Brouillet MD, Wiernik PH. A comparative trial of tobramycin versus gentamicin in combination with vancomycin and nystatin for alimentary tract suppres¬sion in leukemic patients, European Journal of Cancer, 1979, 15, 35-44.
15) Wiernik PH, Gustafson J, Schimpff SC, Diggs CH. Combined modality treatment of Hodgkin's disease confined to lymph nodes: results eight years later, American Journal of Medicine, 1979, 66, 603-610.
16) Wade JC, Schimpff SC, Newman KA, Fortner CL, Moody MR, Young VM, Wiernik PH. Potential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patients, Antimicrobial Agents and Chemotherapy, 1980, 18, 299-306.
17) Wade JC, Newman KA, Schimpff SC, Van Echo DA, Gelber RA, Reed WP, Wiernik PH. Two methods of improved venous access in acute leukemia patients, Journal of the American Medical Association, 1981, 246, 140-144.
18) Wade JC, Schimpff SC, Hargadon MT, Fortner CL, Young VM, Wiernik PH. A comparison of trimethoprim/sulfamethoxazole plus nystatin with gentamicin plus nystatin in the preven¬tion of infections in acute leukemia, New England Journal of Medicine, 1981, 304, 1057-1062.
19) Young VM, Meyers WF, Moody MR, Schimpff SC. The emergence of coryneform bacteria as a cause of nosocomial infections in com¬promised hosts, American Journal of Medicine, 1981, 70, 646-650.
20) Bishop JF, Schimpff SC, Diggs CH, Wiernik PH. Infections in nonHodgkin's lymphoma patients during intensive chemother¬apy, Annals of Internal Medicine, 1981, 95, 549-555.
21) Standiford HC, Viollier AF, Moody M, Klastersky J, Tatem B, Schimpff SC. Antibiotic combinations against gram-negative bacilli and Staphylococcus aureus in cancer patients: comparative in-vitro and in-vivo activity of cefoperazone and mezlocillin singly or combined together, Journal of Antimicrobial Chemotherapy, 1982, 9, 47-49.
22) Wade JC, Wiernik PH, Schimpff SC, Hoofnagle JH, Schiffer CA. Hepatitis among patients with acute nonlymphocytic leukem¬ia, Annals of Internal Medicine, 1983, 75, 413-422.
23) Wade JC, Schimpff SC, Newman KA, Wiernik PH. Staphylococcus epider¬midis: an increasing cause of infection in granulo¬cytopenic pa¬tients, Annals of Internal Medicine, 1982, 97, 503-508.
24) Finley RS, Fortner CL, de Jongh CA, Wade JC, Newman KA, Caplan ES, Brittner J, Wiernik PH, Schimpff SC. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients, Antimicrobial Agents and Chemothera¬py, 1982, 22, 193-197.
25) de Jongh CA, Wade JC, Schimpff SC, Newman KA, Finley RS, Salvatore PC, Moody MR, Standiford HC, Fortner CL, Wiernik PH. Empiric antibiot¬ic therapy for suspected infection in granulocytopenic cancer pa¬tients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin, American Journal of Medicine, 1982, 73, 89-96.
26) Van Sloten K, Wiernik PH, Schiffer CA, Schimpff SC, Aisner J. Evaluation of levamisole as an adjuvant to chemo¬therapy for treat¬ment of ANLL, Cancer, 1983, 51, 1576-1580.
27) Reed WP, Newman KA, de Jongh CA, Wade JC, Schimpff SC, Wiernik PH, McLaughlin JS. Prolonged venous access for chemotherapy by means of the Hickman catheter, Cancer, 1983, 52, 185-192.
28) Drusano GL, Standiford HC, Bustamante CI, Forrest A, Rivera G, Tatem B, Schimpff SC. The plasma pharmacokinetics of high dose (1 gram) imipenem coadministered with 1 gram of cilastatin in six normal volunteers, European Journal of Clinical Microbiology, 1984, 3, 468-470.
29) Reed WP, Newman KA, Tenney JH, Schimpff SC. Autopsy findings after prolonged catheter¬ization of the right atrium for chemotherapy in acute leukemia, Surgery, Gynecology and Obstetrics, 1985, 160, 417-420.
30) Wade JC, Standiford HC, Drusano GL, Johnson DE, Moody MR, Bustamante CI, Joshi JH, de Jongh CA, Schimpff SC. Poten¬tial of imipenem as single-agent empiric antibiotic therapy of febrile neutro¬penic patients with cancer, American Journal of Medicine, 1985, 78 (6A), 62-72.
31) Klastersky J, Schimpff SC, Gaya H, Glauser MP, Zinner SH, and the EORTC Antimicrobial Therapy Project Group. Pro¬spective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic pa¬tients, Antimicrobial Agents and Chemotherapy, 1986, 29, 264-270.
32) Viollier AF, Peterson DE, de Jongh CA, Newman KA, Gray WC, Sutherland JC, Moody MA, Schimpff SC. Aspergillus sinu¬sitis in cancer patients, Cancer 1986, 58, 366-371.
33) de Jongh CA, Joshi JH, Newman KA, Moody MR, Wharton R, Standiford HC, Schimpff SC. Antibiotic synergism and response in gram-nega¬tive bacteremia in granulocytopenic cancer patients, American Journal of Medicine, 1986, 80, 96-100.
34) Khabbaz RF, Kaper JB, Moody MR, Schimpff SC, Tenney JH. Molecu¬lar epidemiology of Group JK Corynebacterium on a cancer ward: lack of evidence for patient-to-patient transmission, Journal of Infectious Diseases, 1986, 154, 95-99.
35) Tchekmedyian NS, Newman K, Moody MR, Costerton JW, Aisner J, Schimpff SC, Reed WP. Case Report: Special studies of the Hickman catheter of a patient with recurrent bacteremia and candidemia. American Journal of the Medical Sciences, 1986, 291, 419-424.
36) EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amika¬cin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia, New England Journal of Medicine, 1987, 317, 1692-1698.
37) European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada--Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocyto¬penic cancer patients. (Schimpff, S.C.--Participant [Consultant]) Journal of Infectious Diseases 1991, 163, 951-958.
38) Schimpff SC, Rapoport MI, O’Keefe SL, Grote DA, Snow LK. The University of Maryland Medical System invests in its community’s minorities. Academic Medicine 1996, 71, 604-612.
39) Schimpff SC, Rapoport MI. The ownership and governance of university teaching hospitals: let form follow function. Academic Medicine 1997, 72, 576-588.